熱門資訊> 正文
bioAffinity Technology启动180万美元直接融资
2025-10-09 04:31
- bioAffinity Technologies (NASDAQ:BIAF) has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules.
- The gross proceeds from the offering are expected to be about $1.8 million. The company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath® Lung, its noninvasive test for lung cancer, and general corporate purposes.
- The closing of the offering is expected to occur on or about October 9, 2025.
- BIAF -3.60% after hours to $2.94.
- Source: Press Release
More on bioAffinity Technologies
- bioAffinity Technologies prices $4.8 million public offering; shares down over 30%
- bioAffinity Technologies announces pricing of private placement
- Seeking Alpha’s Quant Rating on bioAffinity Technologies
- Historical earnings data for bioAffinity Technologies
- Financial information for bioAffinity Technologies
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
